While an effective gene therapy for DMD may require expression of a functional dystrophin protein, restoration of sarcolemmal nNOS alone should substantially ameliorate symptoms associated with functional ischemia in BMD patients. This evidence concerns the gene NOS1 and Becker muscular dystrophy.